Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 12/20 | 0.42 |
| ▸ | CA1 | P00915 | 11/20 | 0.42 |
| ▸ | CA2 | P00918 | 11/20 | 0.42 |
| ▸ | CA9 | Q16790 | 10/20 | 0.42 |
| ▸ | CA4 | P22748 | 7/20 | 0.42 |
| ▸ | CA5A | P35218 | 7/20 | 0.42 |
| ▸ | CA7 | P43166 | 7/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 7/20 | 0.42 |
| ▸ | CA6 | P23280 | 4/20 | 0.42 |
| ▸ | CA13 | Q8N1Q1 | 4/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22330648 | 0.92 | TSHR (0.55) | TSHRPTPN1CA12CA1CA2 | |
| SCHEMBL239643 | 0.92 | TSHR (0.55) | TSHRPTPN1CA12CA1CA2 | |
| SCHEMBL153632 | 0.92 | TSHR (0.55) | TSHRPTPN1CA12CA1CA2 | |
| SCHEMBL16918927 | 0.92 | TSHR (0.55) | TSHRPTPN1CA12CA1CA2 | |
| SCHEMBL13695271 | 0.91 | TSHR (0.54) | TSHRPTPN1CA12CA1CA2 | |
| SCHEMBL153210 | 0.91 | TSHR (0.54) | TSHRPTPN1CA12CA1CA2 | |
| SCHEMBL154770 | 0.91 | TSHR (0.54) | TSHRPTPN1CA12CA1CA2 | |
| SCHEMBL222746 | 0.91 | TSHR (0.54) | TSHRPTPN1CA12CA1CA2 | |
| SCHEMBL24105606 | 0.87 | TSHR (0.50) | TSHRPTPN1CA12CA1CA2 | |
| SCHEMBL24105613 | 0.87 | TSHR (0.56) | TSHRPTPN1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3251679-B1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-12-16 | — | — | EP | disclosed |
| EP-2896397-B2 | Novel compounds having inhibitory activity against sodium-dependant glucose transporter | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-10-07 | — | — | EP | disclosed |
| EP-1651658-B2 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-08-12 | — | — | EP | disclosed |
| US-20180282363-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-10-04 | — | — | US | disclosed |
| EP-3251679-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER | Mitsubishi Tanabe Pharma Corporation (JP) | 2017-12-06 | — | — | EP | disclosed |
| EP-2896397-B1 | Novel compounds having inhibitory activity against sodium-dependant glucose transporter | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-09-06 | — | — | EP | disclosed |
| US-20160108078-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-04-21 | — | — | US | disclosed |
| EP-2896397-A1 | Novel compounds having inhibitory activity against sodium-dependant glucose transporter | Mitsubishi Tanabe Pharma Corporation (JP) | 2015-07-22 | — | — | EP | disclosed |
| EP-2514756-B1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-20140296506-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-10-02 | — | — | US | disclosed |
| EP-2514756-A1 | Novel compounds having inhibitory activity against sodium-dependant glucose transporter | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-10-24 | — | — | EP | disclosed |
| US-20120258913-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-10-11 | — | — | US | disclosed |
| US-8222219-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-07-17 | — | — | US | disclosed |
| US-8202984-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-08 | — | — | US | disclosed |
| US-7943788-B2 | Including the antidiabetic, antiobesity sodium glucose transport inhibitor Canagliflozin (1-( beta -D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene) | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-17 | — | — | US | disclosed |
| US-20110105424-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-05 | — | — | US | disclosed |
| EP-1651658-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | TANABE SEIYAKU CO., LTD. (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-20050233988-A1 | Novel compounds | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-20 | — | — | US | disclosed |
| WO-2005012326-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | TANABE SEIYAKU CO., LTD. (JP) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | TSHR 4300/4885PTPN1 2620/4885CA12 1329/4885 |
| US-20050233988-A1 | Novel compounds | CYP1B1, CYP4B1, CYP2B6 | TSHR 3847/4885PTPN1 3469/4885CA12 977/4885 |
| US-20110105424-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | TSHR 4300/4885PTPN1 2620/4885CA12 1329/4885 |
| US-20120258913-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | TSHR 4300/4885PTPN1 2620/4885CA12 1329/4885 |
| US-20180282363-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | TSHR 4300/4885PTPN1 2620/4885CA12 1329/4885 |
| US-20160108078-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | TSHR 4300/4885PTPN1 2620/4885CA12 1329/4885 |
| US-20140296506-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | TSHR 4300/4885PTPN1 2620/4885CA12 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.